A traditional medical school curriculum does not formally prepare physicians to participate in evaluation of safety and effectiveness after medications enter the market. This article provides examples where ultrasound has unrealized potential as a noninvasive tool for longitudinal assessment of drug safety and effectiveness in the real-world. The examples are intended to sensitize medical schools and medical students to opportunities for physicians to advance therapeutic evaluation of drugs as they are used for approved and unapproved indications in actual practice.
Evaluation of data sources to support pharmacosurveillance. Final Report to Health Policy Research Program, Health Canada. HPRP#6795-15-2001/4410013, July 2004;30.
Pharmacosurveillance In Canada: A background paper prepared for the Working Conference on Strengthening the Evaluation of Real World Drug Safety and Effectiveness. August 2005;31.
Guideline on risk management systems for medicinal products for human use. London: European Medicines Agency, 2005. http://www.emea.europa.eu/pdfs/human/euleg/9626805en.pdf (accessed 17 September 2009).
The new age of pharmacovigilance. MJA 2009;191(3):132-34.
Adverse reactions and the science of pharmacosurveillance. Eur Respir Rev 1998;8(63):1051-53.
Prescription Drug User Fee Act (PDUFA) IV. Drug safety five-year plan. Draft. Silver Spring, Md: FDA, 2008. http://www.fda.gov/downloads/Forindustry/UserFees/PrescriptionDrugUserFee/ucm093946.pdf (accessed 17 September 2009).
Uterine leiomyomata: Medical treatment. In: Brosens I (Ed) Uterine fibroids: Pathogenesis and management. London, New York: Taylor and Francis 2006;237-53.
Ultrasound of uterine fibroids. In: I. Brosens (Ed): Uterine fibroids: Pathogenesis and management. London, New York: Taylor and Francis 2006;139-51.
Ectopic pregnancy. In Donald School Textbook of Ultrasound in Obstetrics and Gynecology 13;230-43.
Forty years of combined oral contraception: The evolution of a revolution MJA 2000;173:541-44.
Effects of continuous versus cyclical oral contraception: A randomized controlled trial. J Clin Endocrinol Metab 2008;93(2):420-29.
Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: Preliminary report. Gynecologic Oncology 2001;81:391-97.
Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: A phase II pilot study. Anticancer Drugs 2002;13:17-24.
Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol 2003;65.
Gynecologic concerns for young women exposed to gonadotoxic chemotherapy. Curr Opin Obstet Gynecol 2003;15:359-70.
Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. The Oncologist 2007;12:1055-66.
Predictors of IVF outcome by threedimensional ultrasound. Hum Reprod 2002;17(4):950-55.